Chapter 7

Figures converted from CHF at historical FX rates — see data/company.json.fx_rates for the rate table. Ratios, margins, and multiples are unitless and unchanged.

The case in one frame

The unusual thing about Sonova is that the bull and the bear start from the same numbers. Both accept that franc sales are flat, that local-currency sales grew 5.9%, that the normalized operating margin has turned up off its trough, and that the roughly 48% de-rating was almost entirely a lower multiple rather than lower earnings [1]. They disagree on interpretation and durability, not on the facts — which is exactly what a synthesis can adjudicate. This chapter reconciles the report into one decision frame and names the filing lines whose thresholds would settle it.

Where bull and bear agree

The single picture that carries the whole disagreement is Sonova's FY2025/26 growth measured two ways. In local currencies the business grew and its profit rose sharply; a strong Swiss franc took most of that back in the reporting currency the shareholder actually banks.

Source: FY2025/26 results release, Group key figures [2]; FY2025/26 Annual Report financial review [3].

The bull reads the left-hand bars: 5.9% local sales, normalized EBITA up 17.3% in local currency to $1,014.5 million, a franc headwind alone cutting that profit by $133.2 million and 1.5 margin points [4]. The bear reads the right-hand bars: a franc holder's reported earnings barely moved on the operating line and fell on the bottom one — basic EPS including discontinued operations dropped 20.3% to $9.04, and return on capital employed slid from 24.1% to 19.0% [5]. Both are looking at the same company. The report's spine — whether the FY2022–24 step-down is cyclical or permanent — lives in the gap between those two bars.

The tension, fact by fact

Each row below is a fact both sides accept, the reading each side takes from it, and the evidence that would decide between them. None of the disputes turn on sentiment; each resolves against a number in a future filing.

Sources: FY2025/26 Annual Report key figures and financial review [6], [7]; Demant FY2025 Annual Report, market and customer risks [8]; prior chapters Moat and OTC Threat, Owners and Stewards, What the Price Implies, Segment Economics.

Two rows deserve a note because they set the direction of the others. Row 4 is where the near-term risk actually sits: Demant, describing the same US market, says over-the-counter devices' impact on the prescription market "remains limited," but that "new form factors … could pose a risk to the prescription hearing aid market, if successful," and — separately and more immediately — that consolidating managed-care organisations "pose a risk to average selling prices" [9]. The sharper 2026 question is price, not demand substitution. Row 5 is where the reward sits: because the de-rating was multiple, not earnings, the outcome is a re-rating question (What the Price Implies).

Three scenarios, one dominant driver

The valuation chapter built the two-year outcome from a single arithmetic: FY2028 normalized earnings times an exit multiple, plus dividends. Reproduced here as the decision frame, it shows what each side has to be right about — and which variable actually moves the answer.

Source: derived in What the Price Implies from FY2025/26 normalized continuing EPS and consensus FY2028 estimates; includes roughly $12.0 of dividends over two years, versus a price of $256.6 (23 July 2026) [10].

Across the range, earnings swing about 19% from bear to bull; the exit multiple swings 50%. The outcome is dominated by re-rating, and re-rating is a judgment about whether the step-down was cyclical. That is why the watch-list below tracks the drivers of the multiple — share, margin, and price discipline — more closely than the earnings line itself.

What to watch

Each item names the line, the filing it appears in (Sonova reports semi-annually — a full-year release in May and a half-year report in November), the current reading, and the threshold that would change the read. All are checkable against a future primary document rather than a headline.

Sources: FY2025/26 results release [11]; FY2025/26 Annual Report financial review [12]; Demant FY2025 Annual Report [13]; US regional sales [14] and Cochlear Implants segment [15], results release.

Two of these are behavioral tests of the new leadership rather than of the business. Whether a management team that repurchased $1.2 billion of stock 40–60% above today's price then stopped as the shares fell now restarts buybacks near $257, and whether it completes the Sennheiser exit cleanly, will say more about future capital discipline than any single quarter of sales (Owners and Stewards).

Weighing the evidence

The balance of the evidence puts the FY2022–24 step-down on the cyclical side. The same margin compression hit the whole industry — Demant's operating margin excluding special items fell to 17.2% [16] — yet Sonova came through it taking hearing-instrument share, its normalized operating margin has turned back up to 22.5%, and against roughly flat normalized continuing earnings the price fell almost entirely on the multiple, which now discounts only market-rate growth [17]. Management's own guidance — 5–8% sales and 7–10% core EBIT growth at constant currency for FY2026/27 — is consistent with that reading [18].

The strongest fact on the other side is that a franc-based owner's realized returns genuinely stepped down: reported EPS including discontinued operations fell 20%, ROCE dropped more than five points, and the margin recovery leans on a single product cycle while management's two largest discretionary calls of the cycle — the buybacks and the Sennheiser deal — both lost money. On this evidence the two-year risk and reward is skewed to the upside at $257, but the outcome is set by the exit multiple rather than the earnings, and the multiple will only re-rate if the Wholesale growth premium and the margin recovery persist past the next competitor platform. That read would flip if Wholesale growth converges toward the 4–6% market, the normalized margin rolls back below roughly 21%, or US selling-price pressure turns explicit in the filings — the first three lines on the watch-list, and the reason to check them before the thesis, not after.